CN107206081A - 治疗炎性疾病的方法 - Google Patents

治疗炎性疾病的方法 Download PDF

Info

Publication number
CN107206081A
CN107206081A CN201680008402.3A CN201680008402A CN107206081A CN 107206081 A CN107206081 A CN 107206081A CN 201680008402 A CN201680008402 A CN 201680008402A CN 107206081 A CN107206081 A CN 107206081A
Authority
CN
China
Prior art keywords
antibody
maintenance dose
patient
weeks
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680008402.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·阿恩特
S·阿斯兰颜
M·R·弗拉克
A·B·加勒
B·拉洛维克
S·J·帕杜拉
P·R·肖勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to CN202110769475.7A priority Critical patent/CN113559258A/zh
Priority to CN202610213213.5A priority patent/CN121944105A/zh
Publication of CN107206081A publication Critical patent/CN107206081A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680008402.3A 2015-02-04 2016-02-02 治疗炎性疾病的方法 Pending CN107206081A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110769475.7A CN113559258A (zh) 2015-02-04 2016-02-02 治疗炎性疾病的方法
CN202610213213.5A CN121944105A (zh) 2015-02-04 2016-02-02 治疗炎性疾病的方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562111731P 2015-02-04 2015-02-04
US62/111,731 2015-02-04
US201562130876P 2015-03-10 2015-03-10
US62/130,876 2015-03-10
US201562135335P 2015-03-19 2015-03-19
US62/135,335 2015-03-19
US201562145764P 2015-04-10 2015-04-10
US62/145,764 2015-04-10
US201562204520P 2015-08-13 2015-08-13
US62/204,520 2015-08-13
US201562235631P 2015-10-01 2015-10-01
US62/235,631 2015-10-01
PCT/US2016/016061 WO2016126638A1 (en) 2015-02-04 2016-02-02 Methods of treating inflammatory diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110769475.7A Division CN113559258A (zh) 2015-02-04 2016-02-02 治疗炎性疾病的方法
CN202610213213.5A Division CN121944105A (zh) 2015-02-04 2016-02-02 治疗炎性疾病的方法

Publications (1)

Publication Number Publication Date
CN107206081A true CN107206081A (zh) 2017-09-26

Family

ID=55453266

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680008402.3A Pending CN107206081A (zh) 2015-02-04 2016-02-02 治疗炎性疾病的方法
CN202110769475.7A Pending CN113559258A (zh) 2015-02-04 2016-02-02 治疗炎性疾病的方法
CN202610213213.5A Pending CN121944105A (zh) 2015-02-04 2016-02-02 治疗炎性疾病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110769475.7A Pending CN113559258A (zh) 2015-02-04 2016-02-02 治疗炎性疾病的方法
CN202610213213.5A Pending CN121944105A (zh) 2015-02-04 2016-02-02 治疗炎性疾病的方法

Country Status (14)

Country Link
US (2) US12441785B2 (https=)
EP (2) EP4670787A3 (https=)
JP (7) JP6758304B2 (https=)
KR (2) KR20170120616A (https=)
CN (3) CN107206081A (https=)
AU (3) AU2016215535B2 (https=)
BR (1) BR112017014684A2 (https=)
CL (1) CL2017001960A1 (https=)
EA (1) EA201791734A1 (https=)
IL (4) IL321788A (https=)
MX (3) MX392789B (https=)
PH (1) PH12017501378A1 (https=)
SG (2) SG10202103879YA (https=)
WO (1) WO2016126638A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114340674A (zh) * 2019-09-09 2022-04-12 勃林格殷格翰国际有限公司 抗-IL-23p19抗体制剂
WO2025051249A1 (zh) * 2023-09-07 2025-03-13 信达生物制药(苏州)有限公司 一种重组抗IL-23p19抗体治疗中重度银屑病的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
AU2016215535B2 (en) * 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
JP6728392B2 (ja) * 2016-04-15 2020-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
CA3037961A1 (en) * 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
CN106778030B (zh) * 2017-01-10 2023-04-07 广州和康医疗技术有限公司 一种强直性脊柱炎病情监测管理系统及其监测管理方法
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
CN111378045B (zh) 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
CA3249485A1 (en) * 2022-01-25 2023-08-03 Sun Pharmaceutical Industries Limited METHODS OF TREATMENT FOR SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101296944A (zh) * 2005-08-31 2008-10-29 先灵公司 工程改造的抗il-23抗体
CN103282382A (zh) * 2010-11-04 2013-09-04 勃林格殷格翰国际有限公司 抗il-23抗体
WO2013165791A1 (en) * 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
JP2000510813A (ja) 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
WO1999040195A1 (en) 1998-02-06 1999-08-12 Schering Corporation Mammalian receptor proteins; related reagents and methods
DE69942607D1 (de) 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
US6367172B2 (en) 1999-07-02 2002-04-09 Bbc International Ltd. Flex sole
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
US20050039222A1 (en) 2001-10-24 2005-02-17 Kiyoshi Habu Sgrf gene-modified non-human animals
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
WO2004042009A2 (en) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
WO2004058178A2 (en) 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
US7282204B2 (en) 2003-03-10 2007-10-16 Schering Corporation Uses of IL-23 agonists and antagonists; related reagents
US7413894B2 (en) 2003-07-01 2008-08-19 University Of Virginia Patent Foundation TAG-1 and TAG-2 proteins and uses thereof
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
KR101128777B1 (ko) 2003-11-04 2012-04-13 조마 테크놀로지 리미티드 다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
CN1942201B (zh) 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
BRPI0510617A (pt) 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
WO2006036922A2 (en) 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7820168B2 (en) 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
CA2612785A1 (en) 2005-06-30 2007-01-11 Archemix Corp. Polynucleotides and polypeptides of the il-12 family of cytokines
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
CN101389769A (zh) 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
WO2007149814A1 (en) 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US20080200591A1 (en) 2007-02-15 2008-08-21 Isao Noda Melt Processable Reactive Pellets Capable of Forming Ester Condensates and Process for Forming Melt Processable Reactive Pellets
CA2675602A1 (en) 2007-02-16 2008-08-21 Wyeth Protein formulations containing sorbitol
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
WO2009032954A1 (en) 2007-09-04 2009-03-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009053493A1 (en) 2007-10-26 2009-04-30 Galderma Research & Development Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
CA2607771A1 (en) 2007-11-01 2009-05-01 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Humanized anti-venezuelan equine encephalitis virus recombinant antibody
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
RU2011126338A (ru) 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010115092A2 (en) 2009-04-02 2010-10-07 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
EP2456787A4 (en) 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
CN102695465A (zh) 2009-12-02 2012-09-26 斯帕泰克医疗股份有限公司 结合具有可偏转柱和复合脊柱杆的骨锚固件的小轮廓脊柱假体
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
JP2013520426A (ja) 2010-02-18 2013-06-06 ブリストル−マイヤーズ スクイブ カンパニー Ｉｌ−２３に結合する、フィブロネクチンをベースとする足場ドメインタンパク質
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
NZ602685A (en) 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
EP2583098B1 (en) 2010-06-15 2018-08-08 Celgene Corporation Biomarkers for the treatment of psoriasis
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
EP2640745B1 (en) 2010-09-10 2018-11-07 MedImmune Limited Bivalent and bispecific anti-il6/anti-il23 antibodies
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
US9078894B2 (en) 2011-02-04 2015-07-14 Ab Science Treatment of severe persistant asthma with masitinib
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
SG11201507482UA (en) * 2013-03-15 2015-10-29 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
SG11201507483PA (en) 2013-03-15 2015-10-29 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
AU2016215535B2 (en) 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
KR20170135972A (ko) 2015-04-14 2017-12-08 베링거 인겔하임 인터내셔날 게엠베하 질환을 치료하는 방법
WO2017015433A2 (en) 2015-07-23 2017-01-26 Boehringer Ingelheim International Gmbh Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
JP6728392B2 (ja) 2016-04-15 2020-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
WO2018033482A1 (en) 2016-08-17 2018-02-22 Boehringer Ingelheim International Gmbh Process for the preparation of highly concentrated liquid formulations containing biomolecules
EP3526252A2 (en) 2016-10-14 2019-08-21 Boehringer Ingelheim International GmbH Methods of treating diseases with il-23a antibody
US20210363233A1 (en) 2018-06-20 2021-11-25 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
JP7090014B2 (ja) * 2018-11-07 2022-06-23 株式会社ミツバ ロータ、モータ、ブラシレスワイパーモータ及びロータの製造方法
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
WO2024085697A1 (en) 2022-10-21 2024-04-25 Chong Kun Dang Pharmaceutical Corp. Stable antibody composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101296944A (zh) * 2005-08-31 2008-10-29 先灵公司 工程改造的抗il-23抗体
CN103282382A (zh) * 2010-11-04 2013-09-04 勃林格殷格翰国际有限公司 抗il-23抗体
WO2013165791A1 (en) * 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114340674A (zh) * 2019-09-09 2022-04-12 勃林格殷格翰国际有限公司 抗-IL-23p19抗体制剂
WO2025051249A1 (zh) * 2023-09-07 2025-03-13 信达生物制药(苏州)有限公司 一种重组抗IL-23p19抗体治疗中重度银屑病的方法

Also Published As

Publication number Publication date
MX2017010037A (es) 2018-05-15
JP7042298B2 (ja) 2022-03-25
EP4670787A2 (en) 2025-12-31
AU2021286378A1 (en) 2022-01-20
KR20240158362A (ko) 2024-11-04
IL307578A (en) 2023-12-01
BR112017014684A2 (en) 2018-01-09
EA201791734A1 (ru) 2018-01-31
JP2025060798A (ja) 2025-04-10
JP7042297B2 (ja) 2022-03-25
JP2020125339A (ja) 2020-08-20
JP2025060797A (ja) 2025-04-10
AU2016215535B2 (en) 2021-09-16
JP2020125338A (ja) 2020-08-20
KR20170120616A (ko) 2017-10-31
SG10202103879YA (en) 2021-05-28
JP2018505882A (ja) 2018-03-01
US20260035453A1 (en) 2026-02-05
IL253118A0 (en) 2017-08-31
NZ733136A (en) 2024-04-26
CA2972995A1 (en) 2016-08-11
JP2020125340A (ja) 2020-08-20
CN121944105A (zh) 2026-05-01
AU2016215535A1 (en) 2017-07-13
CL2017001960A1 (es) 2018-04-20
AU2025204286A1 (en) 2025-07-03
US12441785B2 (en) 2025-10-14
CN113559258A (zh) 2021-10-29
SG11201705728RA (en) 2017-08-30
US20160222102A1 (en) 2016-08-04
EP3253794A1 (en) 2017-12-13
JP2022081644A (ja) 2022-05-31
IL321788A (en) 2025-08-01
MX392789B (es) 2025-03-21
WO2016126638A1 (en) 2016-08-11
EP4670787A3 (en) 2026-04-01
IL323562A (en) 2025-11-01
JP7044824B2 (ja) 2022-03-30
JP6758304B2 (ja) 2020-09-23
PH12017501378A1 (en) 2018-01-08
AU2021286378B2 (en) 2025-03-13
MX2022006573A (es) 2022-07-11
MX2022006575A (es) 2022-07-11

Similar Documents

Publication Publication Date Title
AU2021286378B2 (en) Methods of treating inflammatory diseases
JP7000476B2 (ja) 炎症性疾患の処置法
JP6728392B2 (ja) 炎症性疾患の処置法
JP2017524359A5 (https=)
JP2017524359A (ja) Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
CA2972995C (en) Methods of treating inflammatory diseases
EA046375B1 (ru) Способ лечения воспалительных заболеваний

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination